 |
AbbVie |
Veliparib |
Biodrugs/ Drugs |
Cancer |
Brain cancer, Breast, ovarian and colorectal Cancer, Non-small-cell lung carcinoma (NSCLC)and Small Cell Lung Cancer (SCLC ), Triple-negative breast cancer (TNBC), solid tumors |
3PhIII |
Veliparib
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-8E12 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer |
2PhII |
ABBV-8E12
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-927 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABBV-927
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-927 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABBV-927
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-066 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Psoriasis, Psoriatic arthritis, Crohn disease |
3PhIII |
ABT-066
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABT-122 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Psoriasic arthritis |
2PhII |
ABT-122
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
Rova-T |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
3PhIII |
Rova-T
Therapeutic area:
Cancer
|
|
AbbVie |
SLV245-CREON |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Cystic fibrosis |
3PhIII |
SLV245-CREON
Therapeutic area:
Metabolic / Endocrinology
|
|
AbbVie |
Humira (adalimumab) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Hidradenitis Suppurativa / Peripheral Spondyloarthritis / Uveitis / Ulcerative colitis / Chron Disease / Enthesitis paediatric / AR / Psoriasis |
4Reg. |
Humira (adalimumab)
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-176 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABBV-176
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-414 |
Biodrugs/ Drugs |
Cancer |
Relapsed GBM / Incipient GBM |
3PhIII |
ABT-414
Therapeutic area:
Cancer
|
|
AbbVie |
Atrasentan |
Biodrugs/ Drugs |
Kidney and Genitourinary system |
Diabetic Nephropathy |
3PhIII |
Atrasentan
Therapeutic area:
Kidney and Genitourinary system
|
|
AbbVie |
ABBV-838 |
Biodrugs/ Drugs |
Cancer |
Multiple myeloma |
1PhI |
ABBV-838
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-221 |
Biodrugs/ Drugs |
Cancer |
EGFR (Epidermal growth factor receptor) |
1PhI |
ABBV-221
Therapeutic area:
Cancer
|
|
AbbVie |
Elagolix |
Biodrugs/ Drugs |
Women´s health |
Endometriosis |
3PhIII |
Elagolix
Therapeutic area:
Women´s health
|
|
AbbVie |
ABV-085 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABV-085
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-981 |
Biodrugs/ Drugs |
Analgesia & Pain
Autoimmune & Inflammation |
Knee Osteoarthritis |
2PhII |
ABT-981
Therapeutic area:
Analgesia & Pain / Autoimmune & Inflammation
|
|
AbbVie |
ABT-199/GDC0199 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Multiple mieloma |
3PhIII |
ABT-199/GDC0199
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
AbbVie |
ABT-SLV187 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
4Reg. |
ABT-SLV187
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-181 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
2PhII |
ABBV-181
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-494 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid Arthritis, Crohn Disease |
3PhIII |
ABT-494
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
HCV Interferon-Free Combination (genotype 1) |
Biodrugs/ Drugs |
Infections |
haepatitis C |
3PhIII |
HCV Interferon-Free Combination (genotype 1)
Therapeutic area:
Infections
|
|
AbbVie |
ABBV-621 |
Biodrugs/ Drugs |
Cancer |
Hematology |
1PhI |
ABBV-621
Therapeutic area:
Cancer
|
 |
Amgen |
AMG 334 |
Biodrugs/ Drugs |
Central Nervous System |
Migraine |
2PhII |
AMG 334
Therapeutic area:
Central Nervous System
|
|
Amgen |
Etelcalcetide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Secondary Hyperparathyroidism |
4Reg. |
Etelcalcetide
Therapeutic area:
Metabolic / Endocrinology
|
|
Amgen |
Conatumumab |
Biodrugs/ Drugs |
Cancer |
Various cancer types |
2PhII |
Conatumumab
Therapeutic area:
Cancer
|
|
Amgen |
Romosozumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders
Women´s health |
Postmenopausal osteoporosis |
3PhIII |
Romosozumab
Therapeutic area:
Musculoskeletal Disorders / Women´s health
|
|
Amgen |
AMG 181 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn´s disease |
2PhII |
AMG 181
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Amgen |
Denosumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer |
4Reg. |
Denosumab
Therapeutic area:
Musculoskeletal Disorders
|
|
Amgen |
Denosumab |
Biodrugs/ Drugs |
Cancer |
Giant cell tumour of the bone |
2PhII |
Denosumab
Therapeutic area:
Cancer
|
|
Amgen |
Brodalumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Psoriatic arthritis |
4Reg. |
Brodalumab
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Amgen |
Omecantiv mecarbil |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Heart failure |
3PhIII |
Omecantiv mecarbil
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Amgen |
Brodalumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
4Reg. |
Brodalumab
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Amgen |
Romiplostim |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) |
4Reg. |
Romiplostim
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
Rilotumumab |
Biodrugs/ Drugs |
Cancer |
Various cancer types |
3PhIII |
Rilotumumab
Therapeutic area:
Cancer
|
|
Amgen |
Darbepoetin alfa |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Treatment of symptomatic anemia associated with chronic renal failure in adults / Treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies |
3PhIII |
Darbepoetin alfa
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
Evolocumab |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia |
4Reg. |
Evolocumab
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Amgen |
Blinatumomab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute lymphoblastic leukaemia |
4Reg. |
Blinatumomab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
Talimogene laherparepvec |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma |
4Reg. |
Talimogene laherparepvec
Therapeutic area:
Cancer
|
|
Amgen |
Trebananib |
Biodrugs/ Drugs |
Cancer |
Ovarian Cancer |
3PhIII |
Trebananib
Therapeutic area:
Cancer
|
|
Amgen |
Cinacalcet |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT |
4Reg. |
Cinacalcet
Therapeutic area:
Autoimmune & Inflammation / Kidney and Genitourinary system
|
|
Amgen |
AMG 337 |
Biodrugs/ Drugs |
Cancer |
Gastric cancer |
2PhII |
AMG 337
Therapeutic area:
Cancer
|
 |
Biogen Spain |
Daclizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Multiple Sclerosis |
3PhIII |
Daclizumab
Therapeutic area:
Autoimmune & Inflammation / Central Nervous System
|
|
Biogen Spain |
anti-TWEAK |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Lupus Nephritis |
2PhII |
anti-TWEAK
Therapeutic area:
Autoimmune & Inflammation / Kidney and Genitourinary system
|
|
Biogen Spain |
antiLingo |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Multiple Sclerosis |
2PhII |
antiLingo
Therapeutic area:
Autoimmune & Inflammation / Central Nervous System
|
|
Biogen Spain |
Natalizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Secondary Progressive Multiple Sclerosis |
2PhII |
Natalizumab
Therapeutic area:
Autoimmune & Inflammation / Central Nervous System
|
|
Biogen Spain |
antiLingo |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Optic Neuritis |
2PhII |
antiLingo
Therapeutic area:
Ophthalmology and optometry
|
|
Biogen Spain |
IFN ß 1a pgilated |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Multiple Sclerosis |
4Reg. |
IFN ß 1a pgilated
Therapeutic area:
Autoimmune & Inflammation / Central Nervous System
|
|
Biogen Spain |
BG-12 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Multiple Sclerosis |
4Reg. |
BG-12
Therapeutic area:
Autoimmune & Inflammation / Central Nervous System
|
 |
Celgene |
Ozanimod |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis
Relapsing multiple sclerosis |
3PhIII |
Ozanimod
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
CC-90006 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Autoinmune disorders |
1PhI |
CC-90006
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
Ozanimod |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Crohn`s disease |
2PhII |
Ozanimod
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
AG-881 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute Myeloid Leukemia (AML)
Glioma |
1PhI |
AG-881
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
SOTATERCEPT (ACE-011) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Chronic kidney disease |
2PhII |
SOTATERCEPT (ACE-011)
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
CD19 CAR-T (JCAR017) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Aggressive large B-cell lymphoma: Relapsed/refractory |
1PhI |
CD19 CAR-T (JCAR017)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
BCMA CAR-T (bb2121) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) |
1PhI |
BCMA CAR-T (bb2121)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC-220 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) relapsed/refractory |
1PhI |
CC-220
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
ISTODAX® (romidepsin) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Peripheral T-cell lymphoma:First-line |
3PhIII |
ISTODAX® (romidepsin)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
Citarinostat (ACY-241) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) relapsed/refractory |
1PhI |
Citarinostat (ACY-241)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC-90001 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Fibrosis |
1PhI |
CC-90001
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
REVLIMID® (lenalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse large B-cell lymphoma (ABC subtype): First line
Indolent lymphoma: relapsed/refractory
Follicular lymphoma: first line |
3PhIII |
REVLIMID® (lenalidomide)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma |
1PhI |
CC 486
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
LSD1 Inhibitor: CC-90011 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
LSD1 Inhibitor: CC-90011
Therapeutic area:
Cancer
|
|
Celgene |
PD-L1 Inhibitor:durvalumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Multiple Myeloma (MM)
Chronic Lymphocytic Leukemia (CLL)
No-Hodgkin Lymphoma (NHL) |
1PhI |
PD-L1 Inhibitor:durvalumab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS): lower-risk
Post-induction AML maintenance |
3PhIII |
CC-486
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
ISTODAX® (romidepsin) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Peripheral T-cell lymphoma: relapsed/refractory (Japan) |
2PhII |
ISTODAX® (romidepsin)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
OTEZLA® (apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
OTEZLA® (apremilast)
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
PDA-002 |
Biodrugs/ Drugs |
Others |
Diabetic foot ulcers
Diabetic peripheral neuropathy |
2PhII |
PDA-002
Therapeutic area:
Others
|
|
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Breast: Metastatic
Non-small cell lung: Advanced
Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure |
2PhII |
CC 486
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
Morgensen (GED-0301) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Ulcerative colitis |
2PhII |
Morgensen (GED-0301)
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Celgene |
PNK-007 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM) |
1PhI |
PNK-007
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
OTEZLA® (Apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Ankylosing spondylitis
Behcets disease |
3PhIII |
OTEZLA® (Apremilast)
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Celgene |
AG-221 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
3PhIII |
AG-221
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
RPC4046 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Eosinophilic esophagitis |
2PhII |
RPC4046
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
ABRAXANE® |
Biodrugs/ Drugs |
Cancer |
Pancreatic:Adjuvant |
3PhIII |
ABRAXANE®
Therapeutic area:
Cancer
|
|
Celgene |
AG-120 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
1PhI |
AG-120
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
PD-L1 Inhibitor: durvalumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML) |
2PhII |
PD-L1 Inhibitor: durvalumab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
VIDAZA® (azacitidine for injection) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute myeloid laeukemia (AML) (>30% blasts) |
3PhIII |
VIDAZA® (azacitidine for injection)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CAR-T (JCAR15) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
ALL( Accute Lymphoblastic Leukemia) |
2PhII |
CAR-T (JCAR15)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
Anti-CD47 Antibody: CC-90002 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Solid Tumors |
1PhI |
Anti-CD47 Antibody: CC-90002
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-122 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoma: Diffuse large B-Cell & Indolent lymphoma: relapsed/refractory
Hepatocellular carcinoma
Multiple Myeloma
Chronic Lymphocytic Leukemia (CLL) |
1PhI |
CC-122
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
Mongersen (GED 0301) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
3PhIII |
Mongersen (GED 0301)
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Celgene |
Luspatercept (ACE-536) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Others |
Myelodisplastic Syndromes (MDS)
Beta-thalassemia |
3PhIII |
Luspatercept (ACE-536)
Therapeutic area:
Blood and Lymphatic systems / Others
|
|
Celgene |
CC-90009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
1PhI |
CC-90009
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
PPM Pleiotropic Pathway Modifier: CC-122 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Gliobastoma Multiforme
Hepatocellular carcinoma |
2PhII |
PPM Pleiotropic Pathway Modifier: CC-122
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-220 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Systemic lupus erythematosus |
2PhII |
CC-220
Therapeutic area:
Autoimmune & Inflammation
|
 |
Genzyme |
Alemtuzumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Multiple Sclerosis |
4Reg. |
Alemtuzumab
Therapeutic area:
Autoimmune & Inflammation / Central Nervous System
|
|
Genzyme |
Eliglustat |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Lysosomal Diseases; Gaucher Disease |
4Reg. |
Eliglustat
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes / Metabolic / Endocrinology
|
|
Genzyme |
Aubagio® (teriflunomida) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Multiple Sclerosis |
4Reg. |
Aubagio® (teriflunomida)
Therapeutic area:
Autoimmune & Inflammation / Central Nervous System
|
 |
Gilead Sciences |
GS-6615 (late sodium current inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Ventricular tachycardia / Ventricular fibrillation |
2PhII |
GS-6615 (late sodium current inhibitor)
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC |
Biodrugs/ Drugs |
Infections |
Chronic HBV infection |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Pulmonary arterial hypertension |
2PhII |
GS-4997 (ASK-1 inhibitor)
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Gilead Sciences |
Emtricitabine/Rilpivirine /Tenofovir alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Emtricitabine/Rilpivirine /Tenofovir alafenamide STR
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
GS-5745 (MMP9 mAb inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
GS-5745 (MMP9 mAb inhibitor)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Therapeutic area:
Infections
|
|
Gilead Sciences |
Momelotinib |
Biodrugs/ Drugs |
Cancer |
Pancreatic cancer |
2PhII |
Momelotinib
Therapeutic area:
Cancer
|
|
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Digestive System |
Nonalcoholic steatohaepatitis |
2PhII |
GS-4997 (ASK-1 inhibitor)
Therapeutic area:
Digestive System
|
|
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Digestive System |
Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis |
2PhII |
Simtuzumab
Therapeutic area:
Digestive System
|
|
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Idiopathic pulmonary fibrosis |
2PhII |
Simtuzumab
Therapeutic area:
Respiratory and Pulmonary system
|
|
Gilead Sciences |
Momelotinib |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Myelofibrosis |
3PhIII |
Momelotinib
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Ranolazine |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Incomplete revascularization post-PCI (Percutaneous Coronary Intervention) |
3PhIII |
Ranolazine
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Gilead Sciences |
GS-5806 (fusion inhibitor) |
Biodrugs/ Drugs |
Infections
Respiratory and Pulmonary system |
Respiratory syncytial virus |
2PhII |
GS-5806 (fusion inhibitor)
Therapeutic area:
Infections / Respiratory and Pulmonary system
|
|
Gilead Sciences |
Idelalisib |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Frontline chronic lymphocytic laeukemia, frontline/indolent non-Hodgkin's lymphoma, relapsed refractory CLL |
3PhIII |
Idelalisib
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
 |
LILLY |
insulin-Fc/Dula |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes |
1PhI |
insulin-Fc/Dula
Therapeutic area:
Metabolic / Endocrinology
|
|
LILLY |
Ramucirumab |
Biodrugs/ Drugs |
Cancer |
2nd line hepatocellular carcinoma |
3PhIII |
Ramucirumab
Therapeutic area:
Cancer
|
|
LILLY |
N3pG-AB Monoclonal Antibody |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer |
1PhI |
N3pG-AB Monoclonal Antibody
Therapeutic area:
Central Nervous System
|
|
LILLY |
Ramucirumab |
Biodrugs/ Drugs |
Cancer |
1st line EGFR positive NSCLC |
3PhIII |
Ramucirumab
Therapeutic area:
Cancer
|
|
LILLY |
Tau Antibody |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer |
1PhI |
Tau Antibody
Therapeutic area:
Central Nervous System
|
|
LILLY |
IL-23 antibody |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
ulcerative colitis |
2PhII |
IL-23 antibody
Therapeutic area:
Autoimmune & Inflammation
|
|
LILLY |
Angiopoietin 2 Mab cancer |
Biodrugs/ Drugs |
Cancer |
cancer |
1PhI |
Angiopoietin 2 Mab cancer
Therapeutic area:
Cancer
|
|
LILLY |
Galcanezumab |
Biodrugs/ Drugs |
Analgesia & Pain |
prevention of chronic and episodic migraine |
3PhIII |
Galcanezumab
Therapeutic area:
Analgesia & Pain
|
|
LILLY |
PCSK9 Monoclonal Antibody |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
cardiovascular disease |
2PhII |
PCSK9 Monoclonal Antibody
Therapeutic area:
Cardiovascular and circulatory systems
|
|
LILLY |
CSF-1R Monoclonal Antibody |
Biodrugs/ Drugs |
Cancer |
cancer |
1PhI |
CSF-1R Monoclonal Antibody
Therapeutic area:
Cancer
|
|
LILLY |
Ultra-rapid Insulin |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
2PhII |
Ultra-rapid Insulin
Therapeutic area:
Metabolic / Endocrinology
|
|
LILLY |
FGFR3-ADC |
Biodrugs/ Drugs |
Cancer |
cancer |
1PhI |
FGFR3-ADC
Therapeutic area:
Cancer
|
|
LILLY |
CXCR4 Peptide Antagonist |
Biodrugs/ Drugs |
Cancer |
cancer |
2PhII |
CXCR4 Peptide Antagonist
Therapeutic area:
Cancer
|
|
LILLY |
Oxyntomodulin |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
diabetes |
1PhI |
Oxyntomodulin
Therapeutic area:
Metabolic / Endocrinology
|
|
LILLY |
Emibetuzumab |
Biodrugs/ Drugs |
Cancer |
NSCLC |
2PhII |
Emibetuzumab
Therapeutic area:
Cancer
|
|
LILLY |
PD-L1 Antibody |
Biodrugs/ Drugs |
Cancer |
cancer |
1PhI |
PD-L1 Antibody
Therapeutic area:
Cancer
|
|
LILLY |
BAFF/ IL-17 bispecific antibody |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
immune diseases |
1PhI |
BAFF/ IL-17 bispecific antibody
Therapeutic area:
Autoimmune & Inflammation
|
|
LILLY |
AB42 Antibody Alzheimer´s |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer |
1PhI |
AB42 Antibody Alzheimer´s
Therapeutic area:
Central Nervous System
|
|
LILLY |
CXCR1/2 Ligands Antibody |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
immune diseases |
1PhI |
CXCR1/2 Ligands Antibody
Therapeutic area:
Autoimmune & Inflammation
|
|
LILLY |
Ixekizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
axial spondyloarthritis |
3PhIII |
Ixekizumab
Therapeutic area:
Autoimmune & Inflammation
|
|
LILLY |
IL-21 Antibody |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
immune diseases |
1PhI |
IL-21 Antibody
Therapeutic area:
Autoimmune & Inflammation
|
|
LILLY |
Galcanezumab |
Biodrugs/ Drugs |
Analgesia & Pain |
cluster headache and migraine
prevention of chronic and episodic migraine |
3PhIII |
Galcanezumab
Therapeutic area:
Analgesia & Pain
|
|
LILLY |
GIP/GLP-1 Co-agonist peptide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
diabetes |
1PhI |
GIP/GLP-1 Co-agonist peptide
Therapeutic area:
Metabolic / Endocrinology
|
|
LILLY |
Ramucirumab |
Biodrugs/ Drugs |
Cancer |
second line bladder cancer |
3PhIII |
Ramucirumab
Therapeutic area:
Cancer
|
|
LILLY |
no name |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
hypoglycemia |
1PhI |
no name
Therapeutic area:
Metabolic / Endocrinology
|
|
LILLY |
Ramucirumab |
Biodrugs/ Drugs |
Cancer |
first-line gastric cancer |
3PhIII |
Ramucirumab
Therapeutic area:
Cancer
|
 |
Merck KGaA |
Evofosfamida |
Biodrugs/ Drugs |
Cancer
Dermatology
Digestive System |
Pancreas, cancer, sarcoma |
4Reg. |
Evofosfamida
Therapeutic area:
Cancer / Dermatology / Digestive System
|
|
Merck KGaA |
Pimasertib |
Biodrugs/ Drugs |
Cancer |
Colorectal Cancer, Pancreas, Melanoma, solid tumours and ovarian cancer |
4Reg. |
Pimasertib
Therapeutic area:
Cancer
|
|
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
Several types of cancer |
3PhIII |
Avelumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
Abituzumab |
Biodrugs/ Drugs |
Cancer |
Colorectal Cancer, Prostate cancer, solid tumours |
2PhII |
Abituzumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
Atacicept |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Autoinmune disease |
2PhII |
Atacicept
Therapeutic area:
Autoimmune & Inflammation
|
 |
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Doravirine |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Doravirine
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
20 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Odanacatib |
Biodrugs/ Drugs |
Musculoskeletal Disorders
Women´s health |
Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium |
3PhIII |
Odanacatib
Therapeutic area:
Musculoskeletal Disorders / Women´s health
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Elbasvir/Grazoprevir |
Biodrugs/ Drugs |
Infections |
Chronic Hepatitis C |
3PhIII |
Elbasvir/Grazoprevir
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
10 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Raltegravir |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Raltegravir
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Ph 3 1L Study of Pembrolizumab +/- Ipilimumab in NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
PD-L1 Strong Metastatic Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Etonogestrel+ Estradiol (vaginal ring) |
Biodrugs/ Drugs |
Women´s health |
Contraception |
3PhIII |
Etonogestrel+ Estradiol (vaginal ring)
Therapeutic area:
Women´s health
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with recurrent ovarian cancer |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Fosaprepitant |
Biodrugs/ Drugs |
Cancer |
Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy |
3PhIII |
Fosaprepitant
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
"Phase 3 trial of first line etoposide/platinum with or without
pembrolizumab in extensive stage small cell lung cancer" |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Triple-Negative Breast Cancer (mTNBC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Etonogestrel+ Estradiol (vaginal ring) |
Biodrugs/ Drugs |
Women´s health |
Contraception |
3PhIII |
Etonogestrel+ Estradiol (vaginal ring)
Therapeutic area:
Women´s health
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Sitagliptin |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Type 2 Diabetes |
3PhIII |
Sitagliptin
Therapeutic area:
Metabolic / Endocrinology
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Anacetrapib |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease |
3PhIII |
Anacetrapib
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
MSD |
Gardasil 9 |
Biodrugs/ Drugs |
Infections |
Prevention of HPV infection with Gardasil 9 in adult women 27-45 compared to young adult women (16-26) |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Doravirine |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Doravirine
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced/Unresectable or Metastatic Urothelial Cancer |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
MK3682 |
Biodrugs/ Drugs |
Infections |
Chronic Hepatitis C |
2PhII |
MK3682
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Vacuna |
Vaccines |
Infections |
Staphylococcus aureus Vaccine |
3PhIII |
Vacuna
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
In combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
V920 |
Vaccines |
Infections |
Three consistency lot doses and high dose of rVSV-ZEBOV-GiP (V920 ebola vaccine) in Healthy Adults |
3PhIII |
V920
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) in Advanced Renal Cell Carcinoma (RCC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Suvorexant |
Biodrugs/ Drugs |
Others |
Primary Insomnia |
3PhIII |
Suvorexant
Therapeutic area:
Others
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with lenalidomide and dexamethasone in subjects Multiple Myeloma |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Gardasil 9 |
Biodrugs/ Drugs |
Infections |
V503 in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds) |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Rotavirus Vaccine |
Vaccines |
Infections |
Rotavirus Vaccine |
3PhIII |
Rotavirus Vaccine
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Gardasil 9 |
Biodrugs/ Drugs |
Infections |
2-dose regimen of V503, administered in Preadolescents and Adolescents (9 to 14 year olds) with a Comparison to Young Women (16 to 26 year olds) |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
LAG3 |
Biodrugs/ Drugs |
Cancer |
6 Select Advanced Solid Tumors |
1PhI |
LAG3
Therapeutic area:
Cancer
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia |
1PhI |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
V114 |
Biodrugs/ Drugs |
Infections |
Prevention of Pneumococal infection with V114 comparing to Prevnar 13 in healthy infants |
2PhII |
V114
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with Daratumumab in subjects Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Letermovir |
Biodrugs/ Drugs |
Infections |
Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients |
3PhIII |
Letermovir
Therapeutic area:
Infections
|
|
MSD |
GLP-1R agonist |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Type 2 Diabetes |
2PhII |
GLP-1R agonist
Therapeutic area:
Metabolic / Endocrinology
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. |
3PhIII |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Plus Rituximab Versus Rituximab in Subjects With Relapsed Follicular Lymphoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Inhibitor of human β-site APP cleaving enzyme (BACE1) |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer’s Disease |
3PhIII |
Inhibitor of human β-site APP cleaving enzyme (BACE1)
Therapeutic area:
Central Nervous System
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma (1st line) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Inactivated VZV Vaccine |
Vaccines |
Blood and Lymphatic systems
Cancer |
Adult Patients with Solid Tumor or Hematologic Malignancy |
3PhIII |
Inactivated VZV Vaccine
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
MSD |
BET Inhibitor |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
BET Inhibitor
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil in Subjects with Advanced/Metastatic Esophageal Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
 |
Novo Nordisk Pharma |
AM833 (amilyn analogue) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
AM833 (amilyn analogue)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
G53L (glucagon analogue/liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
G53L (glucagon analogue/liraglutide)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
PYY1562 (analogue peptid YY) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
PYY1562 (analogue peptid YY)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
OI338GT (oral insulin) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
2PhII |
OI338GT (oral insulin)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
IDegAsp (combination insulin degludec + insulin aspart) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 and type 1 |
4Reg. |
IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
IDegLira (combination insulin degludec + liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
4Reg. |
IDegLira (combination insulin degludec + liraglutide)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 in paediatric population |
3PhIII |
Liraglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide 3mg |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
4Reg. |
Liraglutide 3mg
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Nonacog beta pegol |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia B |
4Reg. |
Nonacog beta pegol
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
Turoctocog alfa |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
4Reg. |
Turoctocog alfa
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
N8-GP (glycopegylated recombinant FVIII) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
N8-GP (glycopegylated recombinant FVIII)
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
Insulin LA287 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Insulin LA287
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide NASH |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Non-alcoholic steatohepatitis |
1PhI |
Semaglutide NASH
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide type 1 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 |
3PhIII |
Liraglutide type 1
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Prandial Bioedge |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Prandial Bioedge
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Faster-acting insulin aspart (FIAsp) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and type 2 |
4Reg. |
Faster-acting insulin aspart (FIAsp)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Monoclonal antibody anti Il-21 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 |
2PhII |
Monoclonal antibody anti Il-21
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Somapacitan(Long-acting growth hormone) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Growth hormone deficiency |
3PhIII |
Somapacitan(Long-acting growth hormone)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
OI320GT (oral insulin) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
OI320GT (oral insulin)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Oral semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Oral semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Concizumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A and B |
1PhI |
Concizumab
Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
XOLAIR |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Dermatitis (Allergic Contact) |
3PhIII |
XOLAIR
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
BITOPERTIN |
Biodrugs/ Drugs |
Central Nervous System |
Schizophrenia |
3PhIII |
BITOPERTIN
Therapeutic area:
Central Nervous System
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
OX40
Therapeutic area:
Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
2PhII |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
3PhIII |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Musculoskeletal Disorders |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Systemic lupus erythematosus |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
PLGF MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PLGF MAB
Therapeutic area:
Cancer
|
|
Roche |
NEORECORMON |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Anaemia in neoplastic disease |
2PhII |
NEORECORMON
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
BASIMGLURANT |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Fragile X Syndrome |
2PhII |
BASIMGLURANT
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Peripheral Vascular Diseases |
3PhIII |
ACTEMRA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Other + unspecif. types of non-Hodgkin's lymphoma |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
PATECLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
PATECLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
CMV ANTI |
Biodrugs/ Drugs |
Infections |
Cytomegaloviral disease |
2PhII |
CMV ANTI
Therapeutic area:
Infections
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Thyrotoxicosis (hyperthyroidism) |
3PhIII |
ACTEMRA
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
PEGASYS |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
PEGASYS
Therapeutic area:
Infections
|
|
Roche |
BRAF KIN INH (2) |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
BRAF KIN INH (2)
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
SEMBRAGILINE |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
SEMBRAGILINE
Therapeutic area:
Central Nervous System
|
|
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
2PhII |
POLATUZUMAB VEDOTIN
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
CRENEZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
CRENEZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
3PhIII |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
TAMIFLU |
Biodrugs/ Drugs |
Infections |
Influenza |
3PhIII |
TAMIFLU
Therapeutic area:
Infections
|
|
Roche |
CEA IL2V |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA IL2V
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
DANOPREVIR |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
DANOPREVIR
Therapeutic area:
Infections
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of prostate |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Irritable bowel syndrome |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
TASPOGLUTIDE |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
TASPOGLUTIDE
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
ALPHA7 NIC AGO |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
ALPHA7 NIC AGO
Therapeutic area:
Central Nervous System
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of pancreas |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
GANTENERUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
GANTENERUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
VALCYTE |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Transplanted organ and tissue status (Excl. complications) |
3PhIII |
VALCYTE
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ANTI-INFLUENZA A |
Biodrugs/ Drugs |
Infections |
Influenza |
2PhII |
ANTI-INFLUENZA A
Therapeutic area:
Infections
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Acute myocardial infarction |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Other malignant neoplasms of skin |
1PhI |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
1PhI |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of cervix uteri |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
EM ACTEMAB RA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
EM ACTEMAB RA
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
3PhIII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
LEBRIKIZUMAB |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Other diseases of upper respiratory tract |
2PhII |
LEBRIKIZUMAB
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
EM RA PRED DEV |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM RA PRED DEV
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
CD40 IMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CD40 IMAB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
2PhII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
3PhIII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
MERICITABINE |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
MERICITABINE
Therapeutic area:
Infections
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
HCV POL INH PRO |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
HCV POL INH PRO
Therapeutic area:
Infections
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and unspecified parts of biliary tract |
2PhII |
GAZYVA
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Malignant neoplasms of lymphoid haematopoietic + |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
LAMPALIZUMAB |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
3PhIII |
LAMPALIZUMAB
Therapeutic area:
Ophthalmology and optometry
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cancer |
Other disorders involving the immune mechanism |
2PhII |
ERIVEDGE
Therapeutic area:
Autoimmune & Inflammation / Cancer
|
|
Roche |
CIF MEK INH |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CIF MEK INH
Therapeutic area:
Cancer
|
|
Roche |
GPC3 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of liver |
2PhII |
GPC3 MAB
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Other necrotizing vasculopathies |
3PhIII |
MABTHERA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
FORTOVASE |
Biodrugs/ Drugs |
Infections |
HIV disease unspecified |
2PhII |
FORTOVASE
Therapeutic area:
Infections
|
|
Roche |
EM MS BIOMARKER |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM MS BIOMARKER
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
HPV16 TI |
Biodrugs/ Drugs |
Infections |
Viral agents as cause of diseases classified to other |
2PhII |
HPV16 TI
Therapeutic area:
Infections
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
PARSATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
PARSATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ALECTINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECTINIB
Therapeutic area:
Cancer
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Pemphigus |
3PhIII |
MABTHERA
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
HERCEPTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
2PhII |
HERCEPTIN
Therapeutic area:
Cancer
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
 |
TiGenix |
Cx611 |
Gene / Cell Therapy |
Autoimmune & Inflammation
Infections |
Severe sepsis |
2PhII |
Cx611
Therapeutic area:
Autoimmune & Inflammation / Infections
|
|
TiGenix |
Cx621 |
Gene / Cell Therapy |
Autoimmune & Inflammation |
TBD (Tick-borne diseases) |
1PhI |
Cx621
Therapeutic area:
Autoimmune & Inflammation
|
|
TiGenix |
AlloCSC-01 |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
Acute myocardial infarction |
2PhII |
AlloCSC-01
Therapeutic area:
Cardiovascular and circulatory systems
|
|
TiGenix |
Cx611 |
Gene / Cell Therapy |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
Cx611
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
TiGenix |
Cx601 |
Gene / Cell Therapy |
Autoimmune & Inflammation
Digestive System |
Perianal fistula in Crohn disease patients |
3PhIII |
Cx601
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|